In Brief: ADM Tronics
This article was originally published in The Gray Sheet
Executive Summary
ADM Tronics: Plans to make premarket submission this summer for its Sonotron pulsed radio frequency therapeutic device for the treatment of Carpel and Tarsal Tunnel Syndrome. The submission will include data from 50 patients studied at a single site. Preliminary study data show that out of 30 Carpel Tunnel patients treated with Sonotron, 21 show "improvement in either nerve conduction velocity" or "in the obtained amplitudes of response," ADM Tronics says. Results also show decreased pain, improvement in grip and pinch strength and an improvement in function of the affected hand. The device has been available in Italy and Japan since 1994. The Northvale, New Jersey-based firm also plans to pursue marketing clearance of the device for the treatment of osteoarthritis. ADM had submitted a 510(k) for the Sonotron to treat osteoarthritis ("The Gray Sheet" March 20, 1989, I&W-4), but withdrew the application to collect additional data...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.